A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the tolerability and safety of a
combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).